Literature DB >> 15702478

Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression.

Daniele Calistri1, Claudia Rengucci, Ian Seymour, Arturo Lattuneddu, Anna Maria Polifemo, Franco Monti, Luca Saragoni, Dino Amadori.   

Abstract

Gene mutations in APC, K-ras, and p53 are thought to be essential events for colorectal cancer development. Recent data seem to indicate that K-ras and p53 mutations rarely co-exist in the same tumor, indicating that these alterations do not represent a synergistic evolutionary pathway. Moreover, an inverse relation between K-ras gene activation and BRAF mutations has been demonstrated, suggesting alternative pathways for colorectal cancer transformation. To reconstruct the chronological modulation of these gene mutations during cell transformation and colorectal cancer progression, mutations of p53, K-ras, and BRAF genes were analyzed by Single Strand Conformation Polymorphism (SSCP) or sequencing analysis in 100 colorectal cancer samples, evenly distributed among different Dukes' stages. We found mutations in p53, K-ras, and BRAF genes in 35%, 30%, and 4% of tumors, respectively, and observed a minimal or no co-presence of these gene alterations. Moreover, the frequency of molecular p53 mutations increased as tumor stage increased, suggesting an important role for this gene in the progression of colorectal cancer. Conversely, K-ras or BRAF genes were not related to tumor stage or location. These data seem to indicate the absence of a co-presence of the genes, highlighting the possibility of multiple pathways for colorectal tumor progression. Moreover, mutations in p53, K-ras, and BRAF are not present in about one-third of colorectal cancers and therefore other gene mutations need to be investigated to better understand molecular mechanisms at the basis of cell transformation and the progression of colorectal cancer. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15702478     DOI: 10.1002/jcp.20310

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  40 in total

1.  Characteristics of advanced- and non advanced sporadic polypoid colorectal adenomas: correlation to KRAS mutations.

Authors:  Enkh-Amar Yadamsuren; Szilvia Nagy; Laszlo Pajor; Agnes Lacza; Barna Bogner
Journal:  Pathol Oncol Res       Date:  2012-06-23       Impact factor: 3.201

Review 2.  KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

Authors:  J H J M van Krieken; A Jung; T Kirchner; F Carneiro; R Seruca; F T Bosman; P Quirke; J F Fléjou; T Plato Hansen; G de Hertogh; P Jares; C Langner; G Hoefler; M Ligtenberg; D Tiniakos; S Tejpar; G Bevilacqua; A Ensari
Journal:  Virchows Arch       Date:  2008-09-18       Impact factor: 4.064

3.  Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.

Authors:  Chaar Ines; Ounissi Donia; Boughriba Rahma; Azza Ben Ammar; Amara Sameh; Taher Khalfallah; Ben Hmida Abdelmajid; Mzabi Sabeh; Bouraoui Saadia
Journal:  Tumour Biol       Date:  2014-04-25

4.  Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer.

Authors:  Masahiro Inoue; Shin Takahashi; Hiroshi Soeda; Hideki Shimodaira; Mika Watanabe; Koh Miura; Iwao Sasaki; Shunsuke Kato; Chikashi Ishioka
Journal:  Int J Clin Oncol       Date:  2015-05-20       Impact factor: 3.402

5.  Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern.

Authors:  Humaid O Al-Shamsi; Jeremy Jones; Yazan Fahmawi; Ibrahim Dahbour; Aziz Tabash; Reham Abdel-Wahab; Ahmed O S Abousamra; Kenna R Shaw; Lianchun Xiao; Manal M Hassan; Benjamin R Kipp; Scott Kopetz; Amr S Soliman; Robert R McWilliams; Robert A Wolff
Journal:  J Gastrointest Oncol       Date:  2016-12

Review 6.  Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.

Authors:  Andrea Sartore-Bianchi; Katia Bencardino; Federica Di Nicolantonio; Federico Pozzi; Chiara Funaioli; Valentina Gambi; Sabrina Arena; Miriam Martini; Simona Lamba; Andrea Cassingena; Roberta Schiavo; Alberto Bardelli; Salvatore Siena
Journal:  Target Oncol       Date:  2010-04-11       Impact factor: 4.493

7.  TP53 mutations in colorectal cancer from Tunisia: relationships with site of tumor origin, microsatellite instability and KRAS mutations.

Authors:  Sana Aissi; Marie-Pierre Buisine; Farid Zerimech; Nadia Kourda; Amel Moussa; Mohamed Manai; Nicole Porchet
Journal:  Mol Biol Rep       Date:  2014-01-18       Impact factor: 2.316

8.  Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians.

Authors:  Pooja Malhotra; Mumtaz Anwar; Neha Nanda; Rakesh Kochhar; Jai Dev Wig; Kim Vaiphei; Safrun Mahmood
Journal:  Tumour Biol       Date:  2013-03-24

9.  Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study.

Authors:  Adam Naguib; Panagiota N Mitrou; Laura J Gay; James C Cooke; Robert N Luben; Richard Y Ball; Alison McTaggart; Mark J Arends; Sheila A Rodwell
Journal:  BMC Cancer       Date:  2010-03-16       Impact factor: 4.430

10.  Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin.

Authors:  Manuela Pinheiro; Terje Ahlquist; Stine A Danielsen; Guro E Lind; Isabel Veiga; Carla Pinto; Vera Costa; Luís Afonso; Olga Sousa; Maria Fragoso; Lúcio Santos; Rui Henrique; Paula Lopes; Carlos Lopes; Ragnhild A Lothe; Manuel R Teixeira
Journal:  BMC Cancer       Date:  2010-10-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.